Trading in Knorex Shares Halted Immediately as Delisting Process Begins After Price Falls to $0.0737
Key Facts
NYSE American announced on November 11, 2026, that it had halted trading in Knorex Ltd shares and begun delisting proceedings, citing the stock’s low selling price. The exchange said the company was “no longer suitable for listing” under Section 1003(f)(v) of its company guide. The announcement began the delisting process and suspended trading; it did not complete the delisting on that date. EL7 data show KNRX closed at $0.0737 on November 10, the same level recorded at the November 11 close. Those prices alone do not establish when the suspension took effect during the November 11 session, so that day’s close cannot be treated as the last price before trading was halted.
Trading data show the stock fell before the announcement: it closed at $0.1435 on November 9 and then at $0.0737 on November 10. The stock fell 48.64% on November 10, with about 718.56 thousand shares traded, according to Investing.com data. That rapid decline puts the drop in the selling price at the center of the basis the exchange cited for its decision. But NYSE American’s announcement does not attribute the action to trading volume or another factor; it identifies the low price as the reason the company is unsuitable for listing. The information published here does not detail the effect of the suspension on the stock’s liquidity.
The action gives the company the right to seek a review of the exchange staff’s decision before the Listing Qualifications Committee of the Board of Directors’ Review Committee. NYSE Regulation said the review remained available to the company, without specifying whether Knorex would exercise that right. The step is part of the process preceding a final delisting application; it is not an announcement that an application has already been filed. The exchange said it would file with the U.S. Securities and Exchange Commission to delist the shares after completing the applicable procedures. Those procedures include any appeal filed by the company, making the outcome of the review part of the process preceding the application.
Knorex disclosed in May that it had not filed its annual report on Form 20-F for the year ended December 31, 2025, by the extended deadline of May 15, 2026. The company said at the time that NYSE American would monitor its filing status through November 15, 2026. The disclosure said the exchange could allow the securities to trade for an additional cure period of up to six months, or begin suspension and delisting proceedings at its discretion. This context differs from the reason the exchange gave in its November announcement: a low selling price under Section 1003(f)(v). The annual-report delay therefore remains prior regulatory background, while the November 11 announcement identified the basis for the current suspension and delisting proceedings.
The company’s August filings with the Securities and Exchange Commission provided further financial and regulatory background. Its annual report showed revenue of $6,038,542 in 2025, compared with $10,820,365 in 2024. Knorex also said its net loss was about $11.5 million in 2025, compared with about $5.9 million in 2024. On August 21, the company disclosed a notice from NYSE Regulation that it did not meet the shareholders’ equity standards in Sections 1003(a)(i) and 1003(a)(ii), which are tied to its loss history. The guide sets shareholders’ equity thresholds of $2.0 million and $4.0 million, respectively, under those provisions. These earlier matters remain separate from the stated basis for the November suspension: the low selling price of the shares.
Knorex said in an August disclosure that it intended to submit a compliance plan to NYSE American by September 20, 2026, with the aim of regaining compliance by February 21, 2028. The November 11 announcement does not say whether the plan was submitted or how it related to the delisting action tied to the low price. The next procedural step cited by the exchange is to make a review of the staff decision available, if the company requests one. After completing the applicable procedures, including any appeal, NYSE American said it would file an application to delist with the U.S. Securities and Exchange Commission. Until then, the exchange’s announcement remains an immediate suspension of trading and the start of delisting proceedings, not their completion.